Highlights PolyPid Ltd.

Equities

PYPD

IL0011326795

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-29 pm EDT			5-day change	1st Jan Change
4.772 ^USD	+0.41%		+7.84%	+25.58%

Feb. 14	Transcript : PolyPid Ltd., Q4 2023 Earnings Call, Feb 14, 2024
Feb. 14	PolyPid Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PolyPid Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 14	CI
PolyPid Ltd. Announces Enrollment of the 100th Patient in the Ongoing Shield II Phase 3 Trial	Feb. 12	CI
PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Polypid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-Plex100 and Plex Technology Platform	23-10-04	CI
PolyPid Facility for D-PLEX100 Has no Critical Findings From Israeli Health Ministry Audit	23-09-21	MT
PolyPid to Implement 1-for-30 Reverse Stock Split	23-09-20	MT
PolyPid Ltd. Announces Successful Completion of Manufacturing Process Validation for D-PLEX100	23-09-19	CI
PolyPid Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Polypid Ltd. Announces New Publication Highlighting Potent Antibacterial Activity of D-Plex Against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections	23-06-29	CI
PolyPid Ltd. Announces Recruitment of First Patient in Revised Shield Ii Phase 3 Trial Evaluating D-Plex100 for Prevention of Abdominal Colorectal Surgical Site Infections	23-06-22	CI
PolyPid Ltd Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections	23-05-22	CI
PolyPid Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
PolyPid Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-08	CI
PolyPid Provides Positive Regulatory Update for D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery	23-01-24	CI
Polypid Ltd. Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-Hoc Analysis for D-PLEX in the Prevention of Surgical Site Infections in Abdominal Surgery	23-01-03	CI
PolyPid Says FDA Schedules Type D Meeting to Discuss Late-Stage Study, Regulatory Pathway for D-Plex100	22-12-12	MT
PolyPid Ltd. Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery	22-12-12	CI
PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
PolyPid Gets EMA Nod for Submission of Marketing Authorization Application for D-PLEX100; Shares Rise	22-09-28	MT
Polypid Ltd. Announces Eligibility for European Medicines Agency Centralized Procedure for D-Plex100 for the Prevention of Surgical Site Infections in Abdominal Surgery	22-09-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PolyPid Ltd.

Equities

PYPD

IL0011326795

Highlights

Filters